Bone Health

FDA Approves Teva Biosimilar for Denosumab in Osteoporosis

March 31st 2026

By Sabrina McCrear

The FDA approved Teva’s biosimilar for denosumab, and the FDA and EMA accepted its asthma biosimilar application for review.

Trial Data Support Equivalence of Denosumab Biosimilar in Postmenopausal Osteoporosis

January 16th 2026

By Skylar Jeremias

Denosumab biosimilars enhance treatment access for postmenopausal osteoporosis, demonstrating equivalent efficacy and safety to reference products in recent trials.

Eye on Pharma: Global Approvals, Launches, and Strategic Partnerships

January 12th 2026

By Skylar Jeremias

FDA Approves Amneal Denosumab Biosimilars, Capping Year of Market Expansion

January 6th 2026

By Skylar Jeremias

FDA approves new denosumab biosimilars, enhancing treatment options for osteoporosis and bone metastases while driving competition and cost savings.

Top 5 Most-Read Bone Health Articles of 2025

December 24th 2025

By Skylar Jeremias

Explore the latest advancements in denosumab biosimilars, enhancing treatment options for osteoporosis and bone metastases in 2025.

Denosumab, Golimumab Biosimilars Clear Major Regulatory Milestones in Europe, as US Hurdles Remain

December 16th 2025

By Skylar Jeremias

Biosimilar developers achieve key European approvals for denosumab and golimumab, enhancing patient access while facing US market entry delays.

Economic Analysis Supports Formulary Shift to Biosimilar Denosumab

November 26th 2025

By Skylar Jeremias

Biosimilar denosumab offers significant cost savings and improved access to treatment, alleviating financial burdens in oncology care while enhancing patient outcomes.

FDA Quietly Approves Denosumab Biosimilars, Issues Interchangeability for Others

November 13th 2025

By Skylar Jeremias

FDA approves multiple denosumab biosimilars, enhancing market access and introducing interchangeability, boosting competition in bone health therapies.

EC Approves New Biosimilars for Bone and Eye Conditions

September 19th 2025

By Skylar Jeremias

The European Commission (EC) approves new biosimilars for osteoporosis and eye conditions, enhancing treatment options and patient access across Europe.

FDA Approves Biocon Biologics' Denosumab Biosimilars: Bosaya and Aukelso

September 18th 2025

By Skylar Jeremias

The FDA has approved Bosaya and Aukelso, expanding affordable denosumab biosimilars for osteoporosis and bone-related cancers and enhancing treatment options.